China Approves First Commercial Brain – Computer Interface Implant for Paralysis
Summary:
National Medical Products Administration has approved the first commercial brain–computer interface (BCI) implant developed by Neuracle Technology, designed to help partially paralyzed patients regain hand movement through implanted electrodes connected to a robotic glove. The approval highlights China’s growing investment in BCI technologies as it competes with companies like Neuralink, Synchron, and Precision Neuroscience, alongside new funding rounds for startups such as StairMed and Gestala.
Salspera Targets $91M IPO to Advance Bacteria-Based Cancer Therapy
Summary:
Salspera plans to raise up to $91 million through a Nasdaq IPO to fund phase 3 trials of its lead therapy saltikva, an engineered Salmonella strain designed to stimulate immune responses against cancer by expressing interleukin-2. The therapy has shown promising results in a phase 2 study for metastatic pancreatic cancer and has received orphan drug and fast-track designations from the U.S. Food and Drug Administration, with potential expansion into other solid tumors such as osteosarcoma and colorectal cancer.
FDA Approves Leucovorin for Ultra-Rare Brain Disorder, Not Autism
Summary:
The U.S. Food and Drug Administration has approved the decades-old drug Leucovorin, originally developed by GlaxoSmithKline, to treat cerebral folate deficiency linked to a rare genetic variant – an ultra-rare condition documented in fewer than 50 people. While earlier statements from FDA Commissioner Martin Makary suggested the drug might help children with autism, regulators ultimately concluded that available evidence only supports approval for this rare neurological disorder.
Vima Raises $100M to Develop Oral Therapy for Movement Disorders
Summary:
Vima Therapeutics has raised $100 million to advance VIM0423, a daily oral drug designed to improve motor control in patients with dystonia and Parkinson’s disease. Incubated by Atlas Venture, the biotech plans mid-stage clinical trials with results expected in 2027, aiming to offer a safer alternative to existing treatments that target muscarinic cholinergic receptors.
Rare Disease Drug Market Expected to Surpass $400B by 2032
Summary:
Despite regulatory uncertainty at the U.S. Food and Drug Administration and growing investor focus on blockbuster areas like obesity drugs, global sales of orphan drugs are projected to exceed $400 billion by 2032, accounting for more than 21% of the prescription drug market, according to an Evaluate report. Leading therapies from companies such as Johnson & Johnson, Vertex Pharmaceuticals, and argenx are expected to drive growth, even as policy changes, pricing pressure, and stricter approval standards create ongoing challenges
